Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19819Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Deretzi, G. | en |
| dc.contributor.author | Zou, L. P. | en |
| dc.contributor.author | Pelidou, S. H. | en |
| dc.contributor.author | Nennesmo, I. | en |
| dc.contributor.author | Levi, M. | en |
| dc.contributor.author | Wahren, B. | en |
| dc.contributor.author | Mix, E. | en |
| dc.contributor.author | Zhu, J. | en |
| dc.date.accessioned | 2015-11-24T19:02:37Z | - |
| dc.date.available | 2015-11-24T19:02:37Z | - |
| dc.identifier.issn | 0896-8411 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19819 | - |
| dc.rights | Default Licence | - |
| dc.subject | Administration, Intranasal | en |
| dc.subject | Animals | en |
| dc.subject | Autoimmune Diseases/immunology/pathology/*therapy | en |
| dc.subject | Demyelinating Diseases/immunology/pathology/*therapy | en |
| dc.subject | Disease Models, Animal | en |
| dc.subject | Humans | en |
| dc.subject | Immunoglobulin G/blood/classification | en |
| dc.subject | Interferon-gamma/secretion | en |
| dc.subject | Interleukin-4/*administration & dosage | en |
| dc.subject | Lymphocyte Activation | en |
| dc.subject | Male | en |
| dc.subject | Neuritis/immunology/pathology/*therapy | en |
| dc.subject | Rats | en |
| dc.subject | Rats, Inbred Lew | en |
| dc.subject | Recombinant Proteins/administration & dosage | en |
| dc.title | Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1006/jaut.1998.0259 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10047428 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0896841198902591/1-s2.0-S0896841198902591-main.pdf?_tid=dbc79bafdaabdd7c6e9125f744295200&acdnat=1332844632_e8adf78b9b62b97a8f7c529eb9063397 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1999 | - |
| heal.abstract | Experimental autoimmune neuritis (EAN) is a CD4(+)T cell-mediated demyelinating disease of the peripheral nervous system (PNS) and serves as an experimental model for human immune-demyelinating neuropathies. In this study, we examined the effect of recombinant rat interleukin-4 (rrIL-4) on chronic EAN in Lewis rats induced by immunization with P0 peptide 180-199 and complete Freund's adjuvant (CFA). We estimated that nasal administration of rrIL-4, in dose ranges of 0.1-1 microg/rat/day in the initial phase of EAN, decreased the severity and the duration of clinical EAN. Hyporesponsiveness of T cells, downregulation of Th1 cell responses (INF-gamma), but increased levels of specific IgG1 isotypes document that nasal administration of rrIL-4 was systemically immune effective. Low grade inflammation and complete lack of regional demyelination within the sciatic nerves were seen in rrIL-4 treated rats. Based on these observations we suggest that nasal administration of IL-4 could be further evaluated, considering its possible use in human immune-demyelinating neuropathies. | en |
| heal.journalName | J Autoimmun | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Deretzi-1999-Nasal administration.pdf | 312.75 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
